{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:39:50Z","timestamp":1760146790041,"version":"build-2065373602"},"reference-count":30,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Klinikum N\u00fcrnberg-Paracelsus Medical University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Geriatrics"],"abstract":"<jats:p>We report the case of a 78-year-old female patient who received palliative immunotherapy with pembrolizumab and lenvatinib as a treatment of pulmonary and osseous metastatic endometrial carcinoma. Under this therapy, the patient developed dysphagia, thyroiditis with hypothyroidism, myositis, and myocarditis, which required, due to third-degree AV block, the installation of a pacemaker. The patient received high-dose cortisone therapy, a thyroid hormone substitution, and pyridostigmine for symptom control. With this therapy, we saw a significant but not complete regression of symptoms. Ultimately, we could discharge the patient home for an outpatient treatment. The case report is followed by a discussion of the management of immune-related adverse events (irAEs) during pembrolizumab therapy from a geriatric perspective. Elderly patients on pembrolizumab therapy require close monitoring for irAEs, which can present atypically or without symptoms and may be fatal. Non-invasive diagnostics and minimizing hospital stays are essential to preserve the fitness of this vulnerable population.<\/jats:p>","DOI":"10.3390\/geriatrics9060160","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T12:38:56Z","timestamp":1733920736000},"page":"160","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune-Related Adverse Events in a Patient Treated with Pembrolizumab: A Case Report from the Point of View of a Geriatrician"],"prefix":"10.3390","volume":"9","author":[{"given":"Philipp","family":"Oft","sequence":"first","affiliation":[{"name":"Medizinische Klinik 2\u2013Geriatrie, Klinikum N\u00fcrnberg-Paracelsus Medical University, 90419 Nuremberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Gosch","sequence":"additional","affiliation":[{"name":"Medizinische Klinik 2\u2013Geriatrie, Klinikum N\u00fcrnberg-Paracelsus Medical University, 90419 Nuremberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-532X","authenticated-orcid":false,"given":"Francesco","family":"Pollari","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Herzchirurgie, Klinikum N\u00fcrnberg-Paracelsus Medical University, 90471 Nuremberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1158\/1078-0432.CCR-19-3979","article-title":"FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis","volume":"26","author":"Arora","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.2147\/CMAR.S151023","article-title":"Clinical utility of pembrolizumab in the management of advanced solid tumors: An evidence-based review on the emerging new data","volume":"11","author":"Robert","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Munari, E., Mariotti, F.R., Quatrini, L., Bertoglio, P., Tumino, N., Vacca, P., Eccher, A., Ciompi, F., Brunelli, M., and Martignoni, G. (2021). PD-1\/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105123"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Wang, P.-F., Chen, Y., Song, S.-Y., Wang, T.J., Ji, W.J., Li, S.W., Liu, N., and Yan, C.X. (2017). Immune-Related Adverse Events Associated with Anti-PD-1\/PD-L1 Treatment for Malignancies: A Meta-Analysis. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00730"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e007405","DOI":"10.1161\/CIRCHEARTFAILURE.120.007405","article-title":"Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy","volume":"13","author":"Ammirati","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"ref_8","first-page":"61","article-title":"Functional Evaluation: The Barthel Index","volume":"14","author":"Mahoney","year":"1965","journal-title":"Md. State Med. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","article-title":"The timed \u201cUp & Go\u201d: A test of basic functional mobility for frail elderly persons","volume":"39","author":"Podsiadlo","year":"1991","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00432-019-02927-x","article-title":"Immune checkpoint inhibitor therapy and myocarditis: A systematic review of reported cases","volume":"145","author":"Kadado","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/oncolo\/oyad201","article-title":"Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab","volume":"29","author":"Colombo","year":"2024","journal-title":"Oncologist"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Li, Y., Ren, L., and Zou, J. (2019). Risk Factors and Prevention Strategies of Nosocomial Infection in Geriatric Patients. Can. J. Infect. Dis. Med. Microbiol., 2019.","DOI":"10.1155\/2019\/6417959"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/j.1532-5415.2009.02393.x","article-title":"The Underrecognized Epidemic of Low Mobility During Hospitalization of Older Adults","volume":"57","author":"Brown","year":"2009","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/gerona\/63.10.1076","article-title":"Functional Impact of 10 Days of Bed Rest in Healthy Older Adults","volume":"63","author":"Kortebein","year":"2008","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1111\/j.1532-5415.2011.03644.x","article-title":"Objective Sleep Duration and Quality in Hospitalized Older Adults: Associations with Blood Pressure and Mood","volume":"59","author":"Arora","year":"2011","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.21037\/tlcr-20-1095","article-title":"Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: Plasma exchange as a successful emerging therapy\u2014Case report","volume":"10","author":"Schiopu","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5539\/gjhs.v4n1p65","article-title":"Risks and Complications of Coronary Angiography: A Comprehensive Review","volume":"4","author":"Tavakol","year":"2011","journal-title":"Glob. J. Health Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13256-024-04397-3","article-title":"Pembrolizumab-induced myocarditis with complete atrioventricular block and concomitant myositis in a metastatic bladder cancer patient: A case report and review of the literature","volume":"18","author":"Saad","year":"2024","journal-title":"J. Med. Case Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101145","DOI":"10.1016\/j.eucr.2020.101145","article-title":"Simultaneous pembrolizumab-induced myasthenia gravis and myocarditis in a patient with metastatic bladder cancer: A case report","volume":"31","author":"Takai","year":"2020","journal-title":"Urol. Case Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1536\/ihj.20-162","article-title":"A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma","volume":"61","author":"Matsui","year":"2020","journal-title":"Int. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1038\/ajg.2014.313","article-title":"Oral Corticosteroids and the Risk of Serious Infections in Patients With Elderly-Onset Inflammatory Bowel Diseases","volume":"109","author":"Brassard","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000212608","article-title":"The Complications of Systemic Corticosteroid Therapy in the Elderly","volume":"30","author":"Thomas","year":"1984","journal-title":"Gerontology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2217\/imt-2019-0124","article-title":"Efficacy of Immune Checkpoint Inhibitors and Age in Cancer Patients","volume":"12","author":"Huang","year":"2020","journal-title":"Immunotherapy"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/0284186X.2019.1695062","article-title":"Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: A systematic review and meta-analysis","volume":"59","author":"Ninomiya","year":"2020","journal-title":"Acta Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1001\/jamaoncol.2021.4960","article-title":"Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer","volume":"7","author":"Nebhan","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e001935","DOI":"10.1136\/jitc-2020-001935","article-title":"Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: Study of a population level insurance claims database from the USA","volume":"9","author":"Kalinich","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e000871","DOI":"10.1136\/jitc-2020-000871","article-title":"Impact of age on the toxicity of immune checkpoint inhibition","volume":"8","author":"Samani","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Zhong, X., Sun, J., Zeng, N., Xiong, Y., An, Y., Wang, S., and Xia, Q. (2024). The Effect of Sex on the Therapeutic Efficiency of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials. Cancers, 16.","DOI":"10.3390\/cancers16020382"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Chennamadhavuni, A., Abushahin, L., Jin, N., Presley, C.J., and Manne, A. (2022). Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.779691"}],"container-title":["Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3417\/9\/6\/160\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:52:31Z","timestamp":1760115151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3417\/9\/6\/160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["geriatrics9060160"],"URL":"https:\/\/doi.org\/10.3390\/geriatrics9060160","relation":{},"ISSN":["2308-3417"],"issn-type":[{"type":"electronic","value":"2308-3417"}],"subject":[],"published":{"date-parts":[[2024,12,11]]}}}